List of bibliographic references
Number of relevant bibliographic references: 9.
List of associated KwdEn.i
Nombre de
documents | Descripteur |
|---|
| 5 | Humans |
| 4 | Hyperlipoproteinemia Type II (genetics) |
| 3 | Female |
| 3 | Heterozygote |
| 3 | Middle Aged |
| 3 | Treatment Outcome |
| 2 | Adolescent |
| 2 | Adult |
| 2 | Double-Blind Method |
| 2 | Hyperlipoproteinemia Type II (diagnosis) |
| 2 | Hyperlipoproteinemia Type II (drug therapy) |
| 2 | Hyperlipoproteinemia Type II (therapy) |
| 2 | Male |
| 2 | Young Adult |
| 1 | Access to Information |
| 1 | Antibodies, Monoclonal (administration & dosage) |
| 1 | Antibodies, Monoclonal (adverse effects) |
| 1 | Antibodies, Monoclonal (therapeutic use) |
| 1 | Anticholesteremic Agents (administration & dosage) |
| 1 | Anticholesteremic Agents (adverse effects) |
| 1 | Anticholesteremic Agents (therapeutic use) |
| 1 | Atherosclerosis (diagnosis) |
| 1 | Atherosclerosis (drug therapy) |
| 1 | Carotid Intima-Media Thickness |
| 1 | Child |
| 1 | Cholesterol, LDL (drug effects) |
| 1 | Cholesterol, LDL (metabolism) |
| 1 | Clinical Laboratory Techniques (methods) |
| 1 | Cooperative Behavior |
| 1 | Cost of Illness |
| 1 | Counseling |
| 1 | Data Mining |
| 1 | Delivery of Health Care, Integrated (organization & administration) |
| 1 | Diet |
| 1 | Dietary Supplements |
| 1 | Drug Administration Schedule |
| 1 | Drug Therapy, Combination |
| 1 | Early Diagnosis |
| 1 | Economics, Medical |
| 1 | Endpoint Determination |
| 1 | Europe |
| 1 | Evidence-Based Medicine |
| 1 | Ezetimibe |
| 1 | Genetic Testing |
| 1 | Global Health |
| 1 | Homozygote |
| 1 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use) |
| 1 | Hypercholesterolemia (drug therapy) |
| 1 | Hyperlipoproteinemia Type II (blood) |
| 1 | Hyperlipoproteinemia Type II (epidemiology) |
| 1 | Hyperlipoproteinemia Type II (mortality) |
| 1 | Hyperlipoproteinemia Type II (prevention & control) |
| 1 | Information Storage and Retrieval |
| 1 | Injections, Subcutaneous |
| 1 | International Cooperation |
| 1 | Life Expectancy |
| 1 | Lipoprotein(a) (drug effects) |
| 1 | Medication Adherence |
| 1 | Mutation |
| 1 | Organizational Objectives |
| 1 | Pregnancy |
| 1 | Pregnancy Complications (etiology) |
| 1 | Professional Practice Gaps |
| 1 | Proprotein Convertase 9 |
| 1 | Proprotein Convertases (antagonists & inhibitors) |
| 1 | Receptors, LDL (genetics) |
| 1 | Registries |
| 1 | Research Design |
| 1 | Risk Factors |
| 1 | Serine Endopeptidases |
| 1 | Societies, Medical |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Canada/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i -k "Frederick J. Raal"
HfdIndexSelect -h $EXPLOR_AREA/Data/Canada/Analysis/Author.i \
-Sk "Frederick J. Raal" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Canada/Analysis/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Canada
|étape= Analysis
|type= indexItem
|index= Author.i
|clé= Frederick J. Raal
}}
| This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024 |  |
